Allakos Inc. PT receives Investment Bank Analyst Rating Update
Investing.com - Allakos (NASDAQ:ALLK) reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations. Allakos announced...
Pre-Open Stock Movers: Virios Therapeutics (NASDAQ:VIRI) 63% LOWER; announced topline results from its FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic...
Maxar Technologies Inc. (NYSE:MAXR) finally took out the 4-5-week channel with a pop on Wednesday of 84 cents, or 12%, to 8.01, on 3 million shares. It’s at resistance,...
Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
|Average||6.83 (-7.66% Downside)|
|No. of Analysts||9|